238 related articles for article (PubMed ID: 25483082)
1. Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation.
Podszywalow-Bartnicka P; Wolczyk M; Kusio-Kobialka M; Wolanin K; Skowronek K; Nieborowska-Skorska M; Dasgupta Y; Skorski T; Piwocka K
Cell Cycle; 2014; 13(23):3727-41. PubMed ID: 25483082
[TBL] [Abstract][Full Text] [Related]
2. The downregulation of BAP1 expression by BCR-ABL reduces the stability of BRCA1 in chronic myeloid leukemia.
Dkhissi F; Aggoune D; Pontis J; Sorel N; Piccirilli N; LeCorf A; Guilhot F; Chomel JC; Ait-Si-Ali S; Turhan AG
Exp Hematol; 2015 Sep; 43(9):775-80. PubMed ID: 26118501
[TBL] [Abstract][Full Text] [Related]
3. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
4. RAG enhances BCR-ABL1-positive leukemic cell growth through its endonuclease activity in vitro and in vivo.
Yuan M; Wang Y; Qin M; Zhao X; Chen X; Li D; Miao Y; Otieno Odhiambo W; Liu H; Ma Y; Ji Y
Cancer Sci; 2021 Jul; 112(7):2679-2691. PubMed ID: 33949040
[TBL] [Abstract][Full Text] [Related]
5. BCR-ABL1 kinase-dependent alteration of mRNA metabolism: potential alternatives for therapeutic intervention.
Perrotti D; Harb JG
Leuk Lymphoma; 2011 Feb; 52 Suppl 1(Suppl 1):30-44. PubMed ID: 21299458
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells.
Nimmanapalli R; Bali P; O'Bryan E; Fuino L; Guo F; Wu J; Houghton P; Bhalla K
Cancer Res; 2003 Nov; 63(22):7950-8. PubMed ID: 14633726
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells.
Deutsch E; Jarrousse S; Buet D; Dugray A; Bonnet ML; Vozenin-Brotons MC; Guilhot F; Turhan AG; Feunteun J; Bourhis J
Blood; 2003 Jun; 101(11):4583-8. PubMed ID: 12576338
[TBL] [Abstract][Full Text] [Related]
8. A novel Bcr-Abl-mTOR-eIF4A axis regulates IRES-mediated translation of LEF-1.
Tsai BP; Jimenez J; Lim S; Fitzgerald KD; Zhang M; Chuah CT; Axelrod H; Wilson L; Ong ST; Semler BL; Waterman ML
Open Biol; 2014 Nov; 4(11):140180. PubMed ID: 25392452
[TBL] [Abstract][Full Text] [Related]
9. Targeting Poly(ADP)ribose polymerase in BCR/ABL1-positive cells.
Hiroki H; Ishii Y; Piao J; Namikawa Y; Masutani M; Honda H; Akahane K; Inukai T; Morio T; Takagi M
Sci Rep; 2023 May; 13(1):7588. PubMed ID: 37165001
[TBL] [Abstract][Full Text] [Related]
10. BCR-ABL1 kinase inhibits uracil DNA glycosylase UNG2 to enhance oxidative DNA damage and stimulate genomic instability.
Slupianek A; Falinski R; Znojek P; Stoklosa T; Flis S; Doneddu V; Pytel D; Synowiec E; Blasiak J; Bellacosa A; Skorski T
Leukemia; 2013 Mar; 27(3):629-34. PubMed ID: 23047475
[TBL] [Abstract][Full Text] [Related]
11. BCR-ABL1 mediated miR-150 downregulation through MYC contributed to myeloid differentiation block and drug resistance in chronic myeloid leukemia.
Srutova K; Curik N; Burda P; Savvulidi F; Silvestri G; Trotta R; Klamova H; Pecherkova P; Sovova Z; Koblihova J; Stopka T; Perrotti D; Polakova KM
Haematologica; 2018 Dec; 103(12):2016-2025. PubMed ID: 30049824
[TBL] [Abstract][Full Text] [Related]
12. Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with
Boucher L; Sorel N; Desterke C; Chollet M; Rozalska L; Gallego Hernanz MP; Cayssials E; Raimbault A; Bennaceur-Griscelli A; Turhan AG; Chomel JC
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895120
[TBL] [Abstract][Full Text] [Related]
13. Decreased microRNA-30a levels are associated with enhanced ABL1 and BCR-ABL1 expression in chronic myeloid leukemia.
Liu Y; Song Y; Ma W; Zheng W; Yin H
Leuk Res; 2013 Mar; 37(3):349-56. PubMed ID: 23287430
[TBL] [Abstract][Full Text] [Related]
14. Targeting RAD51 phosphotyrosine-315 to prevent unfaithful recombination repair in BCR-ABL1 leukemia.
Slupianek A; Dasgupta Y; Ren SY; Gurdek E; Donlin M; Nieborowska-Skorska M; Fleury F; Skorski T
Blood; 2011 Jul; 118(4):1062-8. PubMed ID: 21653319
[TBL] [Abstract][Full Text] [Related]
15. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia.
Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C
Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463
[TBL] [Abstract][Full Text] [Related]
16. FAM168A participates in the development of chronic myeloid leukemia via BCR-ABL1/AKT1/NFκB pathway.
Liu X; Mai H; Jiang H; Xing Z; Peng D; Kong Y; Zhu C; Chen Y
BMC Cancer; 2019 Jul; 19(1):679. PubMed ID: 31291942
[TBL] [Abstract][Full Text] [Related]
17. miR-29b suppresses CML cell proliferation and induces apoptosis via regulation of BCR/ABL1 protein.
Li Y; Wang H; Tao K; Xiao Q; Huang Z; Zhong L; Cao W; Wen J; Feng W
Exp Cell Res; 2013 May; 319(8):1094-101. PubMed ID: 23428668
[TBL] [Abstract][Full Text] [Related]
18. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene.
Sharma N; Magistroni V; Piazza R; Citterio S; Mezzatesta C; Khandelwal P; Pirola A; Gambacorti-Passerini C
Mol Cancer; 2015 Jul; 14():132. PubMed ID: 26179066
[TBL] [Abstract][Full Text] [Related]
19. Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia.
Tomasello L; Vezzalini M; Boni C; Bonifacio M; Scaffidi L; Yassin M; Al-Dewik N; Takam Kamga P; Krampera M; Sorio C
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225105
[TBL] [Abstract][Full Text] [Related]
20. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene.
Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P
Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
